SCREENING LICENSES. 28 12.2.1 Tularik Screening Library................................ 28 12.2.2 Roche Bioscience Screening Library....................... 28 12.3
SCREENING LICENSES. KOSAN hereby grants to RWJPRI the following fully paid, non-transferable licenses, with the right to grant sublicenses to RWJPRI AFFILIATES, under the KOSAN PATENT RIGHTS and KOSAN KNOW-HOW to conduct screening pursuant to Article 3:
4.2.1 an exclusive, worldwide license during the EXCLUSIVE SCREENING PERIOD to use the [**];
4.2.2 a non-exclusive, worldwide license during the NON-EXCLUSIVE SCREENING PERIOD:
(a) to use the [**] to conduct screening for [**];
(b) to use the [**] to conduct screening for [**]; and
4.2.3 Subject to the terms and conditions of Section 3.2.1, a non-exclusive, worldwide license during the EXCLUSIVE SCREENING PERIOD and NON-EXCLUSIVE SCREENING PERIOD to use the [**].
SCREENING LICENSES. ArQule hereby grants to Monsanto (a) a nonexclusive, worldwide, royalty-free license (without the right to sublicense) to test Mapping Arrays(TM) against Targets in the Field and to perform other analytical work on the compounds in the Mapping Arrays(TM), and (b) an exclusive (including to the exclusion of ArQule), worldwide, royalty-free license (without the right to sublicense) to test any Directed Arrays(TM) for significant functional activity against Targets in the Field and to perform other analytical work on the compounds in the Directed Arrays(TM).
SCREENING LICENSES. KOSAN hereby grants to RWJPRI the following fully paid, non-transferable licenses, with the right to grant sublicenses to RWJPRI AFFILIATES, under the KOSAN PATENT RIGHTS and KOSAN KNOW-HOW to conduct screening pursuant to Article 3:
4.2.1 an exclusive, worldwide license during the EXCLUSIVE SCREENING PERIOD to use the MACROLIDES [**] ANTIBIOTIC ACTIVITY;
4.2.2 a non-exclusive, worldwide license during the NON-EXCLUSIVE SCREENING PERIOD:
(a) to use the MACROLIDES to conduct screening for ANTIBIOTIC ACTIVITY;
(b) to use the AROMATIC POLYKETIDES to conduct screening for [**]; and
4.2.3 Subject to the terms and conditions of Section 3.2.1, a non-exclusive, worldwide license during the EXCLUSIVE SCREENING PERIOD and NON-EXCLUSIVE SCREENING PERIOD to use the MACROLIDES [**] ANTIBIOTIC ACTIVITY [**] MACROLIDES for MOTILIDE or ANTI-INFLAMMATORY ACTIVITY.
SCREENING LICENSES. (a) Raven hereby grants to ImmunoGen a non-exclusive, royalty-free, fully paid-up license under the Raven Technology and Raven's interest in any Joint Know-How in the United States solely as necessary to carry out the Research hereunder during the Research Term. Such license shall not be sublicensable.
(b) ImmunoGen hereby grants to Raven a non-exclusive, royalty-free, fully paid-up license under the ImmunoGen Technology and ImmunoGen's interest in any Joint Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company's application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act. Know-How in the United States solely as necessary to carry out the Research hereunder during the Research Term. Such license shall not be sublicensable.
SCREENING LICENSES. ArQule hereby grants to Wyeth-Ayerst, under ArQule Patent Rights and ArQule Technology (a) a nonexclusive, royalty-free license * to test each Mapping Array™ for significant functional activity against Targets; and (b) an exclusive, royalty-free license to test each Directed Array™ for significant functional activity against Targets.
SCREENING LICENSES. ArQule hereby grants to Monsanto (a) a nonexclusive, worldwide, royalty-free license (without the right to sublicense) to test Mapping Arrays™ against Targets in the Field and to perform other analytical work on the compounds in the Mapping Arrays™, and (b) an exclusive (including to the exclusion of ArQule), worldwide, royalty-free license (without the right to sublicense) to test any Directed Arrays™ for significant functional activity against Targets in the Field and to perform other analytical work on the compounds in the Directed Arrays™.
SCREENING LICENSES. ArQule hereby grants to Sankyo, under ArQule Patent Rights and ArQule Technology *.
SCREENING LICENSES. ArQule hereby grants to Wyeth-Ayerst, under ArQule Patent Rights and ArQule Technology (a) a nonexclusive, royalty-free license ***** to test each Mapping Array(TM) for significant functional activity against Targets; and (b) an exclusive, royalty-free license to test each Directed Array(TM) for significant functional activity against Targets.
SCREENING LICENSES. ArQule hereby grants to Searxx (x) [*] (b) [*], and (c) [*].
